ACAT II programs are programs that do not meet the criteria for ACAT I and are estimated by the DoD Component head to require an eventual total expenditure for RDT&E of more than $200 million (FY 2020 constant dollars) or, for procurement, of more than $920 million (FY 2020 constant dollars).

2024年2月29日 · The Defense Acquisition System divides acquisition programs into four (4) Acquisition Categories (ACAT): ACAT I, ACAT II, and ACAT III.

ACAT II programs are defined as those acquisition programs that do not meet the criteria for an ACAT I program, but do meet the criteria for a major system as defined in Section 2302d of Title 10, U.S.C.

All major capability acquisition pathway programs are designated by an ACAT. The ACAT identifies the program’s MDA, required processes, and documents. The details regarding ACATs, decision authority and associated policy are presented in Appendix 3A.

The Defense Acquisition System divides acquisition programs into four (4) Acquisition Categories (ACAT): ACAT 1, ACAT 1A, ACAT 2 or ACAT 3. The table below lists the mandatory deliverables (Regulatory & Statutory) at certain milestones for each ACAT type.

2020年9月23日 · In case your answer is no, as a quick public service, I'd encourage you to visit Appendix 3A of the August 2020 DoD Instruction 5000.85 Major Capability Acquisition, entitled simply “ACATs”. This appendix provides descriptions, dollar thresholds, decision authority, and (where appropriate), the statutory requirement.

Purpose: In accordance with DoD Directive (DoDD) 5135.02, this issuance establishes policy and prescribes procedures that guide the acquisition of major capability acquisition programs, including major defense acquisition programs (MDAPs); other programs categorized as acquisition category (ACAT) I; major systems, usually categorized as ACAT II;...

ACAT-2抗体（4A5）是一种小鼠单克隆IgG2a kappa轻链抗体，可通过蛋白质印迹（WB）、免疫沉淀（IP）和酶联免疫吸附测定（ELISA）检测小鼠、大鼠和人类来源的ACAT-2。抗ACAT-2抗体（4A5）以非结合形式提供。

ACAT-2 抑制剂是一类专门的化学实体，可与酰基-CoA：胆固醇酰基转移酶 2（ACAT-2）相互作用。 这种酶在错综复杂的脂质代谢过程中发挥着重要作用。 它的主要功能是催化胆固醇和其他脂质分子的酯化过程。 ACAT-2 抑制剂的显著特点在于其精确的分子结构，使其能够干预 ACAT-2 的酶活性。 这样，这些抑制剂就能阻碍酯化的自然进程，而酯化是细胞管理胆固醇的一个重要步骤。 这些抑制剂通过与 ACAT-2 酶的活性位点结合，产生分子相互作用，从而破坏其有效催化胆固 …

2024年12月24日 · ACAT2 (Acetyl-CoA Acetyltransferase 2) is a Protein Coding gene. Diseases associated with ACAT2 include Alpha-Methylacetoacetic Aciduria and Acetyl-Coa Acetyltransferase-2 Deficiency. Among its related pathways are superpathway of cholesterol biosynthesis and Ketone body metabolism.